I-Mab(US:IMAB) Jin Rong Jie·2025-07-30 13:40Core Viewpoint - Tianjing Bio (IMAB) is focused on developing innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases, aiming to fill clinical treatment gaps and improve patient survival globally [2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, with the actual date subject to company announcement [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to become a leading biopharmaceutical company rooted in China and oriented towards global markets [2].